Next Article in Journal
Report from the Scientific Poster Session at the 13th Annual Cardiometabolic Health Congress in Boston, USA, 24–27 October 2018
Previous Article in Journal
From Rapid Recommendation to Online Preference-Sensitive Decision Support: The Case of Severe Aortic Stenosis
Previous Article in Special Issue
Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis
Open AccessReview

Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes

1
Servei Pneumologia, Hospital Universitari Son Espases, 07010 Palma Mallorca, Spain
2
Institut de Investigacio Sanitària de les Illes Balears (IdISBa), 07120 Palma Mallorca, Spain
3
CIBER Enfermedades Respiratorias, Insituto Carlos III, 28029 Madrid, Spain
4
Instituto de Investigación, Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, 28006 Madrid, Spain
*
Author to whom correspondence should be addressed.
Scientific and Methodological Consultant of SEPAR.
Med. Sci. 2018, 6(4), 110; https://doi.org/10.3390/medsci6040110
Received: 7 September 2018 / Revised: 16 November 2018 / Accepted: 21 November 2018 / Published: 29 November 2018
(This article belongs to the Special Issue Idiopathic Pulmonary Fibrosis)
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is characterized by a chronic, progressive, fibrotic interstitial lung disease of unknown cause that occurs primarily in older adults. Its prevalence and incidence have appeared to be increasing over the last decades. Despite its unknown nature, several genetic and environmental factors have been associated with IPF. Moreover, its natural history is variable, but could change depending on the currently suggested phenotypes: rapidly progressive IPF, familial, combined pulmonary fibrosis and emphysema, pulmonary hypertension, and that associated with connective tissue diseases. Early recognition and accurate staging are likely to improve outcomes and induce a prompt initiation of antifibrotics therapy. Treatment is expected to be more effective in the early stages of the disease, while developments in treatment aim to improve the current median survival of 3–4 years after diagnosis. View Full-Text
Keywords: idiopathic pulmonary fibrosis; prevalence; incidence; evolution; risk factors; comorbidities idiopathic pulmonary fibrosis; prevalence; incidence; evolution; risk factors; comorbidities
Show Figures

Figure 1

MDPI and ACS Style

Sauleda, J.; Núñez, B.; Sala, E.; Soriano, J.B. Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med. Sci. 2018, 6, 110.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop